High importance
Aug 24, 2026
To inform about the FDA's decision to add a boxed warning to ferric carboxymaltose (FCM) regarding the risk of serious hypophosphatemia following a citizen petition led by Dr. Scott Olitsky from Cure HHT.
The research involved submitting a citizen petition to the FDA addressing safety concerns associated with ferric carboxymaltose, specifically focusing on its side effect profile and the implications for patients with hereditary hemorrhagic telangiectasia (HHT).
The FDA acknowledged the concerns and implemented a boxed warning for FCM, indicating increased awareness of the potential for serious hypophosphatemia, which may affect patient management and treatment protocols for those with HHT.
The limitations of the petition process may include the reliance on existing data regarding adverse effects and the timeframe for regulatory changes, which may not fully encompass long-term safety implications or patient experiences.
This decision is critical as it enhances drug safety awareness for a vulnerable patient population (HHT) and informs healthcare providers of significant risks associated with an increasingly utilized treatment, promoting more cautious prescribing practices.
The FDA has granted a citizen petition led by Cure HHT’s Dr. Scott Olitsky, adding a boxed warning to ferric carboxymaltose (FCM), commonly marketed under brand names like Injectafer or Ferinject, for the risk of serious hypophosphatemia. Learn what this change means for people with HHT, their caregivers, and the healthcare professionals who treat them. The post FDA Adds Boxed Warning to Ferric Carboxymaltose Following Petition Led by Cure HHT’s Dr. Scott Olitsky appeared first on CureHHT.